Cite
Clinical utility of [ 68 Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.
MLA
Zhao, Liang, et al. “Clinical Utility of [ 68 Ga]Ga-Labeled Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography/Computed Tomography for Primary Staging and Recurrence Detection in Nasopharyngeal Carcinoma.” European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. 11, Oct. 2021, pp. 3606–17. EBSCOhost, https://doi.org/10.1007/s00259-021-05336-w.
APA
Zhao, L., Pang, Y., Zheng, H., Han, C., Gu, J., Sun, L., Wu, H., Wu, S., Lin, Q., & Chen, H. (2021). Clinical utility of [ 68 Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 48(11), 3606–3617. https://doi.org/10.1007/s00259-021-05336-w
Chicago
Zhao, Liang, Yizhen Pang, Hua Zheng, Chengkun Han, Jianwei Gu, Long Sun, Hua Wu, Sangang Wu, Qin Lin, and Haojun Chen. 2021. “Clinical Utility of [ 68 Ga]Ga-Labeled Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography/Computed Tomography for Primary Staging and Recurrence Detection in Nasopharyngeal Carcinoma.” European Journal of Nuclear Medicine and Molecular Imaging 48 (11): 3606–17. doi:10.1007/s00259-021-05336-w.